摘要
目的 探讨在化疗基础上利用重组人白细胞介素 2 (IL 2 )治疗老年急性髓细胞白血病 (AML)的临床价值。 方法 选择 1994～ 2 0 0 1年收住的老年人AML 41例分别作为观察组和对照组。观察组 2 1例在联合化疗基础上加用IL 2治疗 ,对照组 2 0例单用联合化疗 ,随访观察疗效。 结果 患者对IL 2耐受性良好 ,观察组完全缓解 (CR)率、达CR所需时间与对照组无显著差异 [38 1%vs 35 0 % ,( 5 3 2± 2 1 3)dvs ( 5 5 8± 2 3 1)d ,P >0 0 5 ]。但缓解期和生存期长短优于对照组 [( 9 8± 4 8)月vs ( 5 3± 2 3)月 ,P <0 0 5 ;( 9 3± 2 8)月vs ( 6 1± 2 5 )月 ,P <0 0 0 1]。 结论 对老年人AML在化疗的基础上给予IL
Objective To evaluate the clinical value of recombinant human interleukin 2(IL 2)in the treatment of senle acute myelogenous leukemia(AML)on the basis of chemotherapy. Methods Forty one cases of elderly patients with AML were admitted from 1994 to 2001.Observation group (21)was treated with IL 2 on the basis of combined chemotherapy.Control group(20)was treated only with combined chemotherapy.Both groups were followed up to observe the effects. Results IL 2 was tolerated well by the patients.The difference between the two groups in complete remission(CR)rate(38 1% vs 35 0%) and the time to acquire CR(53 2±21 3)d vs (55 8±23 1)d, P >0 05)was not significant,but duration of CR [(9 8±4 8)months vs (5 3±2 3)months, P <0 05],and survival time[(9 3±2 8)months vs (6 1±2 5)months, P <0 001] of observation group was longer than that of control group. Conclusions The use of IL 2 on the basis of chemotherapy is effective and feasible for prolongation of CR and survival duration in elderly patients with AML.
出处
《实用老年医学》
CAS
2002年第2期94-96,共3页
Practical Geriatrics
